tiprankstipranks
Trending News
More News >

Chimeric Therapeutics Lists New Securities on ASX

Story Highlights
Chimeric Therapeutics Lists New Securities on ASX

Don’t Miss TipRanks’ Half-Year Sale

An announcement from Chimeric Therapeutics Ltd. ( (AU:CHM) ) is now available.

Chimeric Therapeutics Limited has announced the quotation of 200,000 ordinary fully paid securities on the Australian Securities Exchange (ASX) as of May 28, 2025. This move is part of the company’s strategy to enhance its financial flexibility and support its ongoing development projects, potentially strengthening its position in the competitive biotechnology market.

More about Chimeric Therapeutics Ltd.

Chimeric Therapeutics Limited operates in the biotechnology industry, focusing on developing innovative therapies for cancer treatment. The company specializes in chimeric antigen receptor T cell (CAR-T) therapies, aiming to provide advanced solutions for patients with difficult-to-treat cancers.

Technical Sentiment Signal: Sell

Current Market Cap: A$8.06M

See more data about CHM stock on TipRanks’ Stock Analysis page.

Disclaimer & DisclosureReport an Issue

Looking for investment ideas? Subscribe to our Smart Investor newsletter for weekly expert stock picks!
Get real-time notifications on news & analysis, curated for your stock watchlist. Download the TipRanks app today! Get the App
1